Compare Consolidated Edison, Inc. (ED) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Novo Nordisk A/S — how do they compare? Consolidated Edison, Inc. trades at $111.98 (market cap $40.65B), while Novo Nordisk A/S trades at $51.37 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 5.5× Consolidated Edison, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| ED | NVO | |
|---|---|---|
Market Cap | $40.65B | $222.24B |
Sector | Utilities | Health |
52-Week High | $115.46 | $71.70 |
52-Week Low | $95.37 | $35.29 |
Enterprise Value | $67.68B | $241.20B |
Dividend Yield | 3.15% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $111.58, down 0.32% on the day, with a bullish technical signal and strong fundamental performance. The utility company reported Q3 and Q4 2025 earnings beats but missed Q1 2026 estimates, with Q2 2026 results due August 6. ED maintains solid profitability with 12.52% net income margin and $2.02B net income in 2025, supported by $4.8B operating cash flow. Recent news highlights grid upgrades for AI data center demand and electric school bus fleet expansion.
ED offers stable dividend income with a 3.3% yield and 52-year growth streak, but faces mixed analyst sentiment (62.96% hold rating) and consensus price target of $103.50 below current price. Key risks include rising interest expenses ($1.23B in 2025) and capital-intensive grid modernization. The stock presents value for income investors despite near-term execution challenges.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
